Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for ...
Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...
Regeneron Pharmaceuticals and Sanofi said a key European regulatory committee has recommended expanded approval of their blockbuster anti-inflammatory drug Dupixent for younger patients with the ...
Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...
Sanofi and Regeneron’ s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment. If approved, Dupixent would be the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results